ABSTRACT

 The aim of this present study was to investigate the in vitro antidiabetic effect of * plumbagin isolated Irom plumbago zeylanica on pancreatic lipase, alpha amylase, alpha glucosidase and its mode of inhibition on these enzymes and its effect on protein glycation. The compound dissolved in %1 dimethylsulfoxide (DMSO) for pancreatic lipase, alpha glucosidase and alpha amylase assays and absolute dimelhysulfoxide for protein glycation was examined at concentrations of 50, 25, 12.5. 6.25. 3.125 and 1.56pg/ml. The antidiabetic effect was found to be concentration dependent. The compound showed a significant percentage inhibition on alpha amylase and alpha glucosidase at concentration of 50pg/ml with 75.95 and 79.85% respectively when compared with the standard drug acarbose with percentage inhibition of 78.52% while pancreatic lipase was weakly inhibited by the compound having percentage inhibition of 33.51% at hightest concentration of 50pg/ml when compared to orlistat at concentration of 50|ig/ml with percentage inhibition of 57.48%. Also, the compound moderatly inhibited protein glycation with percentage of 69 and 66% compared to aminoguanidine which showed a percentage inhibition of 82% when induced with glucose and fructose respectively. In addition, plumbagin was shown to be a competitive, uncompetitive and mixed inhibitor of alpha amylase, alpha glucosidase and pancreatic lipase respectively. From the results obtained plumbagin can be used as a therapeutic agent with fewer side effects however, further studies are needed to determine the in vivo effect of plumbagin and its level oftoxicity.